— First-in-class oral inhibitor designed to selectively target SIK2 to suppress inflammation and promote resolution and tissue repair — — Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NDI-225673 in healthy volunteers — BOSTON, Mass. — November 10, 2026 — Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a computational drug discovery … Continue reading “Nimbus Therapeutics Announces First-in-Human Dosing of NDI-225673, an Investigational Selective SIK2 Inhibitor for Immune-Mediated Inflammatory Diseases” The post Nimbus Therapeutics